Velocity-Based Resistance Training Effects on Inflammation in Older Adults
4 mai 2026 mis à jour par: National Taipei University
Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults.
Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group.
Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase.
The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
60
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Shun-Hsi Tsai, Ph.D.
- Numéro de téléphone: 68523 +88686741111
- E-mail: shunhsi@mail.ntpu.edu.tw
Lieux d'étude
-
-
-
Taipei, Taïwan, 116
- Recrutement
- National Taiwan Normal University
-
Contact:
- Hung-Wen Liu, Ph.D.
- Numéro de téléphone: +88677496863
- E-mail: hwliu@ntnu.edu.tw
-
Contact:
- Kuan-Tsen Yeh, M.S.
- Numéro de téléphone: +886932815383
- E-mail: mickyyehyeh@gmail.com
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Aged 60-75 years or older
- No regular resistance training habit (defined as ≥2 sessions per week) in the past year
- No musculoskeletal injuries within the past six months
Exclusion Criteria:
- Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
- Regular use of anti-inflammatory medications (e.g., NSAIDs).
- Smoking or alcohol abuse
- Inability to safely perform the prescribed resistance exercise movements
- Unable to fully comprehend the study information and instructions.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% from the first repetition.
Rest intervals of 2-3 minutes will be provided between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Expérimental: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Expérimental: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM.
Each set will be terminated when movement velocity decreases by 30% relative to the first repetition.
Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
|
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions.
All sessions will be supervised by research personnel to ensure proper technique and safety.
Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
|
|
Aucune intervention: sedentary control
Participants in control trial stayed sedentary during the period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in IL-6 concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Plasma IL-6 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble IL-6 receptor concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in soluble gp130 concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Soluble gp130 concentrations will be measured and reported in ng/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-10 concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-10 concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-1RA concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
IL-1RA concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in TNF-α concentration
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
TNF-α concentrations will be measured and reported in pg/mL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Borgs Ratings of Perceived Exertion (RPE)
Délai: 1-hour during each exercise intervention
|
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
|
1-hour during each exercise intervention
|
|
Handgrip strength
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Knee extension strength
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
30-second chair-stand test
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Single-leg balance test
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Timed up and go test
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in gp130 (CD130) protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in STAT3 protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in phosphorylated STAT3 protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in SOCS3 protein expression in PBMCs
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in white blood cell count
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total white blood cell count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in lymphocyte count
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Lymphocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in neutrophil count
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Neutrophil count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Changes in monocyte count
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Monocyte count will be measured and reported in cells/μL.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Body fat percentage
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
|
Lean body mass
Délai: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
|
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Shun-Hsi Tsai, Ph.D., National Taipei University
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
20 avril 2026
Achèvement primaire (Estimé)
1 mars 2029
Achèvement de l'étude (Estimé)
1 décembre 2029
Dates d'inscription aux études
Première soumission
15 avril 2026
Première soumission répondant aux critères de contrôle qualité
28 avril 2026
Première publication (Réel)
5 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
4 mai 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Activité motrice
- Mouvement
- Phénomènes physiologiques musculo-squelettiques
- Phénomènes physiologiques musculo-squelettiques et neuronaux
- Thérapeutique
- Modalités de physiothérapie
- Soins aux patients
- Thérapie d'exercice
- Réhabilitation
- Suivi
- Continuité des soins aux patients
- Conditionnement physique, humain
- Exercice
- Formation en résistance
Autres numéros d'identification d'étude
- ECKIRB1140803
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .